Exploring The Impact of AI Technologies on Oncology Practice
Artificial intelligence may act as a force multiplier, with the automation of menial tasks enabling more time for clinicians to engage with patients.
Promising Clinical Activity in UTUC Lesions With Enfortumab Vedotin Plus Pembrolizumab
New data from a small retrospective analysis showed activity with enfortumab vedotin and pembrolizumab in UTUC lesions.
Enfortumab Vedotin PFS May Improve Despite Specific AEs in Bladder Cancer
Patients with neuropathy experienced a longer PFS with enfortumab vedotin vs those without neuropathy, skin rash, or hyperglycemia.
Adjuvant Nivolumab Shows Sustained DFS Benefit in High-Risk Bladder Cancer
Data from CheckMate-274 support adjuvant nivolumab as a standard of care in high-risk muscle-invasive urothelial carcinoma.
Neoadjuvant Chemotherapy Plus Chemoradiotherapy Displays Efficacy in MIBC
Investigators assessed the long-term outcomes of neoadjuvant chemotherapy plus chemoradiation in those with non-metastatic muscle-invasive bladder cancer.
Expert Insights into the T-DXd Approval for HER2-Low or Ultralow Breast Cancer
Aditya Bardia, MD, discusses the FDA approval of T-DXd for HER2-low or ultralow metastatic breast cancer and its potential impact on treatment paradigms.
FDA Approves Vimseltinib in Tenosynovial Giant Cell Tumor
Vimseltinib elicited an ORR of 40% vs 0% of matching placebo in patients with tenosynovial giant cell tumor in the phase 3 MOTION trial.
Loncastuximab Tesirine Elicits Robust Responses in R/R Follicular Lymphoma
The toxicity profile of loncastuximab tesirine plus rituximab was consistent with prior clinical trials assessing each agent as monotherapy.
Fish Oil and a High Omega-3 Diet Reduced Prostate Ki-67 Index
Patients who did not receive fish oil experienced a Ki-67 index increase of 24% vs the 15% Ki-67 index decrease for patients with a low omega-6, high omega-3 diet who received fish oil.
Nivolumab/Relatlimab Does Not Meet RFS End Point in Stage III/IV Melanoma
The safety profile of nivolumab plus relatlimab in patients with stage III/IV melanoma was consistent with the known profiles for each individual agent.
Post-HSCT Defibrotide Does Not Reduce Sinusoidal Obstruction Syndrome
Prophylactic defibrotide conferred more ICU admissions and higher mortality among high-risk pediatric patients who underwent prior HSCT.
Highlighting AI Diagnostic and Prognostic Developments in Oncology Care
Artificial intelligence may have the potential to enrich pathology practices to help identify aspects of tumor biology not seen with the human eye.
Outlining Incidence Trends and Disparities of MZL
Potential contributing factors of marginal zone lymphoma (MZL) were highlighted in a recent discussion with James R. Cerhan, MD, PhD.
Darolutamide/ADT Improves Outcomes in mHSPC Across Disease Volumes
The ARANOTE phase 3 trial showed darolutamide plus ADT improved outcomes in mHSPC regardless of disease volume.
Addition of AI to Mammogram Screenings Bolsters Cancer Detection Rates
Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.
Maintaining Docetaxel Dose Intensity in mHSPC with G-CSF in ARASENS Regimen
Phase 3 ARASENS trial results highlight the role of G-CSF in optimizing docetaxel delivery within the darolutamide-based regimen for mHSPC.
EBRT Regimens Elicit 15-Year Prostate Cancer Survival Outcomes
More adverse factors occurred in those with intermediate-risk prostate cancer undergoing neoadjuvant androgen deprivation therapy than those who did not.
DESTINY-Breast06 Efficacy Surpasses SOC in HER2-Low/Ultralow Breast Cancer
Findings from DESTINY-Breast06 showed a PFS of 13.2 months for patients given T-DXd for HER2-low or ultralow breast cancer.
UCBT Yields Excellent Efficacy Outcomes in Hematologic Malignancies
The analysis saw minimal evidence of increased relapse among patients with hematologic cancers and minimal residual disease vs those without.
Anakinra Ineffective in Preventing CRS/ICANS After Liso-cel in LBCL
Anakinra prophylaxis did not significantly decrease the incidence or severity of CRS or ICANS in patients with LBCL treated with liso-cel.
Sotorasib Combo Has Positive PFS Impact in KRAS G12C-Mutated CRC
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
Obe-Cel Is Effective in R/R B-ALL Patients with Low CAR-HT Risk
Obe-cel shows efficacy in R/R B-ALL, especially in those with a favorable CAR-HT risk profile, according to data from the phase 1/2 FELIX study.
Tuspetinib Triplet Therapy Achieves Early Responses in AML
A total of 3 patients with AML treated with the lowest dose of tuspetinib at 40 mg completed the first cycle of treatment with no dose-limiting toxicities.
Talazoparib and Enzalutamide Improve Outcomes in Advanced Prostate Cancer
The TALAPRO-2 trial revealed promising survival data for patients with metastatic CRPC treated with talazoparib and enzalutamide.
Neoadjuvant Nivolumab Combo Boosts Pathologic Response in ER+ Breast Cancer
Data from the CheckMate 7FL trial may inform treatment decisions regarding preoperative immunotherapy for patients with breast cancer.
Highlighting Quality of Life Considerations for MZL Treatment
Juan Alderuccio, MD, discussed treatment strategies for MZL, particularly as they relate to quality of life, and the role of prognosis models on treatment.
INB-100 After HSCT Shows Enduring Efficacy in Complex Leukemias
Early INB-100 results showed the potential to achieve durable remissions and improve survival in patients with complex leukemias, particularly AML.
A Look at Upcoming Impactful Presentations at ASCO GU 2025
The 2025 Genitourinary Cancers Symposium will feature key updates in the management of different bladder, prostate, and kidney cancer populations.
Retreatment With Pertuzumab/T-DM1 Improves PFS in HER2+ Breast Cancer
Pertuzumab retreatment modestly improved progression-free survival and meaningfully improved overall survival in advanced nHER2–positive breast cancer.
T-DXd Approval Appears Significant in HER2-Low/Ultralow Breast Cancer
Aditya Bardia, MD, MPH, FASCO, spoke about how the FDA approval of T-DXd in HER2-low or ultralow breast cancer will allow for a broader treatment range.
